Marie Gårdmark: New incentives for orphan products on its way

"Let’s hope that the learnings from development of new therapies for rare diseases will spill over to more common conditions, orphan products paving the wave for drug development in a broader context", writes Marie Gårdmark in a column.

IVI’s Director General on establishing in Sweden: Will need up to 40 employees

The International Vaccine Institute, IVI, hopes to have its first staff on-site in Stockholm within a couple of months, says the institute’s Director General Jerome Kim in an interview with Life Science Sweden.

Now it’s settled: The International Vaccine Institute will be located in Stockholm

The International Vaccine Institute, IVI, is establishing itself outside South Korea for the first time. Last week, the Swedish Parliament ratified the agreement, which means that a branch of the institute will be located in Stockholm.

Start-up developing ”digital twin” received award during the EIT Health Summit

A biotech company, a medtech company and a company in digital health were on the podium when the EIT Health Catapult awarded its winners.

Hello Angelica Loskog!

Life Science Sweden would like to know more about Angelica Loskog and interviews her about her life as a researcher.

Pharm Assist köps av ny koncern inom life science-tjänster

Konsultbolaget Pharm Assist Sweden har köpts upp och kommer tillsammans med det norska investmentbolaget Serendipity och kontraktsforskningsföretaget Link Medical att ingå i en ny nordeuropeisk koncern för tjänster inom life science.

Serendipity går in som storägare i Link

Det norska kontraktsforskningsföretaget Link Medical ingår ett partnerskap med Serendipity partners, som går in som delägare och långsiktig investerare i bolaget.

Paolo Macchiarini in court – “The sole intent was to cure”

Paolo Macchiarini’s surgical procedure was illegal, life-threatening and caused severe and prolonged suffering to patients the prosecution claimed when the trial against the Italian surgeon began on Wednesday last week.

We will now publish more news in English – and offer yet another newsletter

Starting next week, Life Science Sweden will begin offering a newsletter entirely in English.

Elicera develops CAR-T against solid tumours – may become the first in the world

Today, there are five EU-approved CAR-T therapies, all focused on different types of blood cancer, but no one has yet succeeded in making the method work against solid tumours. At Gothenburg-based Elicera, they are working relentlessly to succeed in that field as well. “It is the largest field, and the potential is enormous,” says the company’s CEO Jamal El-Mosleh.

The route to vaccines for everyone: “We did not just sit around and wait”

The pandemic was in full swing, and no one knew when or even if a vaccine would come. At that point, the Swedish Minister of Social Affairs called with a proposal, and Richard Bergström did not hesitate. “I already had a notion that this would work,” he says in an interview with Life Science Sweden.

Giulia Gaudenzi: Innovation for good

"I challenge the innovator landscape to take a mental leap. Relying on innovation-solely to end inequality is not enough, therefore consciously and purposively – we need to engage bravely with the politics of poverty and scarcity. Even in life sciences", writes Giulia Gaudenzi in a column.

Genterapier och vaccin dryftas på branschmötet

Pharma Outsourcing igång på Stockholm Waterfront

Organon köper Forendo Pharma i miljardaffär

Amerikanska Organon köper Forendo Pharma som utvecklar läkemedel mot endometrios.

The Oresund region aims at becoming Europe’s microbiome Mecca

The Medicon Valley Alliance’s ambition: Skåne and the Copenhagen region will become world leaders in microbiome research.

Link Medical värvar från KI

Det norska kontraktsforskningsföretaget Link Medical har rekryterat Maria Hortlund som RWE Manager.

Sweden and Denmark – this is how they choose their strategies

Scandinavia’s two major powers in pharmaceutical research have developed strategies for growth in life science, and both countries aim to become world leaders.

MVA:s CEO: “Our investments should improve people´s everyday lives”

Involuntary infertility and diabetes are two of the areas on the agenda of the Medicon Valley Alliance.

Norska Link Medical samarbetar med finskt företag

Det norska CRO-företaget Link Medical och finska Medaffcon ska via ett samarbete erbjuda företag i Norden real world evidence-studier.

Norway finds its path in life science

The life science sector in Norway is on the rise.

Marie Gårdmark: Big data evidence generation drives change in the EU regulatory system

Rapid developments in technology have led to the possibility for the generation and analysis of vast volumes of data. Will the availability of big data lead to fundamental changes to the regulatory system? In a column Marie Gårdmark, CEO and Senior

Column: Repurposing as a golden ticket to approval

"Hopefully, in the end, patients will be winners by receiving on-label treatments for which benefit-risk has been properly assessed." In a column Marie Gårdmark, CEO at RegSmart Life Science, reflects on drug repurposing.

Samuel Lagercrantz: Collaboration and joint efforts are the key to success

Although many questions about Covid-19 remain unanswered, the development of drugs and vaccines has been incredibly rapid, writes Samuel Lagercrantz, Life Science Sweden´s Editor-in-Chief, in an editorial.